Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab?
Higher DWMH burden, as quantified by the Fazekas score, is significantly associated with ARIA risk in patients with AD treated with lecanemab. These findings suggest that DWMH may serve as a potential imaging biomarker for ARIA risk stratification. Larger studies incorporating additional vascular biomarkers, including cerebral amyloid angiopathy markers, are warranted to refine risk prediction models.
Authors
- Javier M. Romero (ORCID: https://orcid.org/0000-0001-5749-3000)
- Jeremy N. Ford
- Liliana Ramírez Gómez (ORCID: https://orcid.org/0000-0001-8869-3240)
- Jarrel Seah (ORCID: https://orcid.org/0000-0002-2305-7873)
- Helen Griffin (ORCID: https://orcid.org/0000-0002-5288-3322)
- Maryam Vejdani‐Jahromi (ORCID: https://orcid.org/0000-0002-4503-6264)
- Esteban Calle (ORCID: https://orcid.org/0009-0001-5805-5720)
- Raymond Y. Huang (ORCID: https://orcid.org/0000-0001-7661-797X)
- Saurabh Rohatgi (ORCID: https://orcid.org/0000-0002-4000-7878)
- Benjamin M. Kozak (ORCID: https://orcid.org/0000-0001-8291-8971)
- John R. Dickson (ORCID: https://orcid.org/0000-0003-0135-7928)
- Teresa Gómez‐Isla (ORCID: https://orcid.org/0000-0002-7977-2075)
- Nima Omid‐Fard (ORCID: https://orcid.org/0000-0002-2255-9476)
- Shenghua Zhu
- Hana Farzaneh
- Odette Ganem Chagui
Institutions
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- American Journal of Neuroradiology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3174/ajnr.a8822
- Primary Topic
- Cerebrospinal fluid and hydrocephalus
- Type
- article
- Field-Weighted Citation Impact
- 0.00